Anavex Life Sciences Corp (AVXL)

[Investor2014]

For re-examination new data cannot be added, new analysis on existing data provided with the MAA can. If we assume that all the available trial participant gene data was included, then the question becomes if the GWAS database extract is considered data that should have been part if the MAA or if it passes as necessary external input to the analysis.

Maybe someone can do the exercise with ChatGPT to see if an answer with references can be pinned down.